These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 26490356

  • 21. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
    Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T.
    Lung Cancer; 2015 May; 88(2):181-6. PubMed ID: 25726043
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 24. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q, Zhou C.
    Int J Cancer; 2012 Sep 01; 131(5):E822-9. PubMed ID: 22161771
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX, Yang JY, Xu YF, Zhang M, Zhang XP, Chen WY, Lv XD.
    Math Biosci Eng; 2019 Jun 19; 16(5):5687-5696. PubMed ID: 31499732
    [Abstract] [Full Text] [Related]

  • 28. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Okuda Y, Sato K, Sudo K, Hasegawa Y, Asano M, Miura H, Takeda M, Sano M, Watanabe H, Kobayashi H, Niioka T, Miura M, Ito H.
    Cancer Chemother Pharmacol; 2017 May 19; 79(5):1013-1020. PubMed ID: 28391354
    [Abstract] [Full Text] [Related]

  • 29. Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
    Choi YW, Choi JH.
    Korean J Intern Med; 2017 May 19; 32(3):422-428. PubMed ID: 28352061
    [Abstract] [Full Text] [Related]

  • 30. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [Abstract] [Full Text] [Related]

  • 31. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B.
    Lung Cancer; 2016 Jun 01; 96():87-92. PubMed ID: 27133756
    [Abstract] [Full Text] [Related]

  • 32. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
    Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD.
    Br J Cancer; 2015 Nov 17; 113(10):1519-28. PubMed ID: 26461059
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
    Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL.
    Lung Cancer; 2014 Jul 17; 85(1):66-73. PubMed ID: 24780111
    [Abstract] [Full Text] [Related]

  • 34. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.
    Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte P, Pasello G.
    Oncotarget; 2017 May 16; 8(20):32626-32638. PubMed ID: 28427238
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.
    Ovcaricek T, Cufer T, Kern I, Sodja E, Sadikov A.
    J Cancer Res Ther; 2013 May 16; 9(2):261-6. PubMed ID: 23771370
    [Abstract] [Full Text] [Related]

  • 38. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.
    Zhang Y, Kang S, Fang W, Hong S, Liang W, Yan Y, Qin T, Tang Y, Sheng J, Zhang L.
    Clin Lung Cancer; 2015 Mar 16; 16(2):144-151.e1. PubMed ID: 25454007
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.
    Xu J, Zhang Y, Jin B, Chu T, Dong X, Yang H, Wu D, Lou Y, Zhang X, Wang H, Han B.
    J Cancer Res Clin Oncol; 2016 Jun 16; 142(6):1325-30. PubMed ID: 26942444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.